Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Receives $34.33 Consensus Price Target from Brokerages

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) has received an average rating of “Hold” from the eight analysts that are presently covering the company, MarketBeat reports. Seven research analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $30.6667.

Several analysts have recently weighed in on LKFT shares. Morgan Stanley cut their price objective on Lakefront Biotherapeutics American Depositary Shares from $30.00 to $26.00 and set an “equal weight” rating for the company in a report on Tuesday. Wall Street Zen lowered Lakefront Biotherapeutics American Depositary Shares from a “buy” rating to a “hold” rating in a report on Saturday, May 16th. Zacks Research upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “strong sell” rating to a “hold” rating in a research report on Monday, June 8th. Weiss Ratings lowered shares of Lakefront Biotherapeutics American Depositary Shares from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, August 4th. Finally, Royal Bank Of Canada lowered their price objective on shares of Lakefront Biotherapeutics American Depositary Shares from $28.00 to $26.00 and set a “sector perform” rating on the stock in a research note on Tuesday, August 11th.

Lakefront Biotherapeutics American Depositary Shares Price Performance

Shares of NASDAQ:LKFT opened at $27.53 on Tuesday. Lakefront Biotherapeutics American Depositary Shares has a 12 month low of $25.68 and a 12 month high of $37.78. The stock has a market cap of $1.81 billion, a price-to-earnings ratio of -19.52 and a beta of 0.27. The stock’s 50 day moving average price is $28.68 and its 200 day moving average price is $29.97.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) last released its earnings results on Monday, August 10th. The biotechnology company reported $0.04 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.97) by $1.01. The firm had revenue of $15.47 million during the quarter, compared to analyst estimates of $7.29 million. On average, sell-side analysts expect that Lakefront Biotherapeutics American Depositary Shares will post -1.29 EPS for the current year.

Institutional Trading of Lakefront Biotherapeutics American Depositary Shares

A number of large investors have recently added to or reduced their stakes in the business. State of Wyoming bought a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the second quarter valued at $28,000. Van ECK Associates Corp lifted its position in shares of Lakefront Biotherapeutics American Depositary Shares by 61.6% during the 4th quarter. Van ECK Associates Corp now owns 1,968 shares of the biotechnology company’s stock valued at $64,000 after acquiring an additional 750 shares during the last quarter. Arax Advisory Partners boosted its stake in shares of Lakefront Biotherapeutics American Depositary Shares by 319.2% during the 4th quarter. Arax Advisory Partners now owns 2,335 shares of the biotechnology company’s stock worth $76,000 after acquiring an additional 1,778 shares in the last quarter. Quadrant Capital Group LLC bought a new stake in shares of Lakefront Biotherapeutics American Depositary Shares during the 3rd quarter worth $134,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Lakefront Biotherapeutics American Depositary Shares in the 3rd quarter worth $211,000. 32.46% of the stock is currently owned by institutional investors.

About Lakefront Biotherapeutics American Depositary Shares

Galapagos NV (NASDAQ:GLPG) is a clinical-stage biotechnology company headquartered in Mechelen, Belgium, focused on the discovery and development of novel small-molecule therapies. Established in 1999 through the merger of Tibotec and Progenix, Galapagos has built a research platform targeting chronic inflammatory diseases, fibrosis and oncology. The company’s discovery engine integrates human genetics, translational biology and medicinal chemistry to identify and optimize drug candidates with unique modes of action.

The company’s pipeline encompasses multiple programs across various stages of development.